Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.

FDA clears first over-the-counter wearable device for continuous glucose monitoring
The newly cleared device is worn on the back of the arm and sends data directly to the user's smartphone.
Are GLP-1 agonists safe? FDA finds no evidence popular weight loss medications cause suicidal thoughts or actions
The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.
‘A true breakthrough’: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity
While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.
Roche spends $2.7B to acquire biotech company with multiple obesity, diabetes drugs in development
Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.
CVD deaths have increased dramatically, undoing years of progress
The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all?

Dexcom, a global healthcare technology company based out of San Diego, has received the first over-the-counter U.S. Food and Drug Administration (FDA) clearance for a wearable glucose biosensor that can be obtained without a prescription, the Stelo..

FDA clears first over-the-counter wearable device for continuous glucose monitoring

The newly cleared device is worn on the back of the arm and sends data directly to the user's smartphone.

March 6, 2024

doctor with overweight patient who may be treated with TAVR or surgery

Are GLP-1 agonists safe? FDA finds no evidence popular weight loss medications cause suicidal thoughts or actions

The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.

January 11, 2024

‘A true breakthrough’: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

December 15, 2023

healthcare money economics dollar stethoscope acquire merger

Roche spends $2.7B to acquire biotech company with multiple obesity, diabetes drugs in development

Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

December 4, 2023

American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.

CVD deaths have increased dramatically, undoing years of progress

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all?

November 15, 2023

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved.

September 14, 2023

The U.S. Food and Drug Administration (FDA) has approved Recor Medical’s Paradise Ultrasound Renal Denervation (RDN) system for uncontrolled hypertension. The Recor system gained FDA clearance in November 2023.

FDA panel votes in favor of Recor Medical renal denervation system

A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval.

August 23, 2023

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

August 8, 2023

Around the web

Cardiovascular Business

Cardiology groups share key update: ABMS seeking feedback on proposed Board of Cardiovascular Medicine

Five of the largest U.S. medical societies focused on cardiovascular health are one step closer to seeing their paradigm-shifting proposal become a reality.

Cardiovascular Business

Cardiologists, thoracic surgeons applaud FTC’s ban of most noncompete clauses

The Society for Cardiovascular Angiography & Interventions and Society of Thoracic Surgeons have both shared statements in support of the ban, which is already being challenged in court. The American Hospital Association, meanwhile, opposes the policy shift, saying it “errs by seeking to create a one-size-fits-all rule”

Cardiovascular Business

Why the business side of cardiology was a key focus at ACC.24

Alison Bailey, MD, co-chair of the business of cardiology sessions at ACC.24, emphasized that reimbursement cuts can have a long-term negative impact on patient.